Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement GlobeNewswire - Fri Aug 21, 7:30AM CDT

MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment GlobeNewswire - Thu Aug 20, 7:30AM CDT

MOUNTAIN VIEW, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth GlobeNewswire - Wed Aug 12, 3:05PM CDT

Increases 2026 Annual Revenue Guidance to a Range of $3.75M to  $4.25M First Treatment Delivered with RenovoCath ® in Patient with Sarcoma in Clinical Setting, Marking Expansion of Device...

RNXT : 1.3200 (unch)
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer GlobeNewswire - Tue Aug 11, 7:30AM CDT

MOUNTAIN VIEW, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors GlobeNewswire - Thu Aug 6, 7:30AM CDT

MOUNTAIN VIEW, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th GlobeNewswire - Tue Aug 4, 7:30AM CDT

MOUNTAIN VIEW, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) ( Nasdaq: RNXT ), a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET GlobeNewswire - Wed Jul 29, 7:30AM CDT

MOUNTAIN VIEW, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)
iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today ACCESS Newswire - Tue Jun 23, 7:15AM CDT

RALEIGH, NC / ACCESS Newswire / June 23, 2026 / iAccess Alpha's Virtual Best Ideas Summer Investment Conference begins today, bringing together small and micro-cap public companies and investors for a...

ECOR : 10.89 (+3.52%)
BOSC : 4.65 (-0.85%)
MYO : 1.5900 (-8.09%)
AMROF : 0.2350 (+11.90%)
ROC : 4.09 (-2.62%)
EXYN : 2.02 (-8.60%)
ACCS : 4.96 (+0.20%)
SKYX : 1.1500 (unch)
NNBR : 3.84 (+1.69%)
TII : 2.80 (-0.71%)
TI : 5.63 (+0.36%)
MIND : 4.57 (+0.81%)
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026 ACCESS Newswire - Thu Jun 18, 8:00AM CDT

RALEIGH, NC / ACCESS Newswire / June 18, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Summer Investment Conference on June 23-24, 2026, bringing together small and micro-cap...

ECOR : 10.89 (+3.52%)
BOSC : 4.65 (-0.85%)
MYO : 1.5900 (-8.09%)
AMROF : 0.2350 (+11.90%)
ROC : 4.09 (-2.62%)
EXYN : 2.02 (-8.60%)
ACCS : 4.96 (+0.20%)
SKYX : 1.1500 (unch)
NNBR : 3.84 (+1.69%)
TII : 2.80 (-0.71%)
TI.TO : 3.91 (+14.66%)
MIND : 4.57 (+0.81%)
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer GlobeNewswire - Thu Jun 11, 7:30AM CDT

MOUNTAIN VIEW, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life-sciences company developing innovative targeted oncology therapies...

RNXT : 1.3200 (unch)

Barchart Exclusives

A 75-Day Seasonal Sell Window Is Opening in the Euro—Are You Prepared? Barchart - 57 minutes ago
What happens when seasonality, inflation, crude oil, and interest rates all begin pointing toward the same trade?The euro is approaching a 75-day seasonal sell window—and the fundamental backdrop may be lining up with it.Is the next bearish opportunity taking shape? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.